A Phase 1 interventional study of LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received escalating oral doses of LY3502970 according to the following dosing schedule: * Days 1-7: 2 milligrams (mg) once daily (QD) * Days 8-14: 4 mg QD * Days 15-21: 8 mg QD
Drug: LY3502970
Participants received 16 mg LY3502970 Formulation 1 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 2 orally QD from Days 29-35 in test period 2.
Drug: LY3502970
Participants received 16 mg LY3502970 Formulation 2 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 1 orally QD from Days 29-35 in test period 2.
Drug: LY3502970
Administered orally.
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2
PK: Cmax of LY3502970 in Formulation 1 and Formulation 2
Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
PK:(AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2
PK: Tmax of LY3502970 in Formulation 1 and Formulation 2
Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
| Milestone | 2 mg/4mg/8mg LY3502970 - Dose Titration Period | 16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period | 16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period |
|---|---|---|---|
| Started | 39 | 0 | 0 |
| Received at least one dose of ly3502970 | 38 | 0 | 0 |
| Completed | 34 | 0 | 0 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Milestone | 2 mg/4mg/8mg LY3502970 - Dose Titration Period | 16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period | 16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period |
|---|---|---|---|
| Started | 0 | 17 | 17 |
| Received at least one dose of ly3502970 | 0 | 17 | 17 |
| Completed | 0 | 17 | 16 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | 2 mg/4mg/8mg LY3502970 - Dose Titration Period | 16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period | 16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period |
|---|---|---|---|
| Started | 0 | 17 | 16 |
| Received at least one dose of ly3502970 | 0 | 17 | 16 |
| Completed | 0 | 17 | 15 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
PK: Cmax of LY3502970 in Formulation 1 and Formulation 2
| nanogram per milliliter (ng/mL) | 16 mg LY3502970 (Formulation 1) | 16 mg LY3502970 (Formulation 2) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2 | 86.5 ± 40 | 86.5 ± 43 |
PK:(AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
| Nanogram*hour per milliliter (ng*h/mL) | 16 mg LY3502970 (Formulation 1) | 16 mg LY3502970 (Formulation 2) |
|---|---|---|
| PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2 | 1260 ± 38 | 1240 ± 40 |
PK: Tmax of LY3502970 in Formulation 1 and Formulation 2
| Hours (h) | 16 mg LY3502970 (Formulation 1) | 16 mg LY3502970 (Formulation 2) |
|---|---|---|
| PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2 | 6.00 (4.00 to 23.92) | 6.00 (2.00 to 12.00) |
Collected over From baseline until end of follow-up (up to 49 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2 mg LY3502970 - Dose Titration Period | 0/38 (0%) | 0/38 (0%) | 23/38 (60.5%) |
| 4 mg LY3502970 - Dose Titration Period | 0/37 (0%) | 0/37 (0%) | 8/37 (21.6%) |
| 8 mg LY3502970 - Dose Titration Period | 0/34 (0%) | 0/34 (0%) | 17/34 (50%) |
| 16 mg LY3502970 (Formulation 1) | 0/33 (0%) | 0/33 (0%) | 24/33 (72.7%) |
| 16 mg LY3502970 (Formulation 2) | 0/34 (0%) | 0/34 (0%) | 24/34 (70.6%) |
| Event | 2 mg LY3502970 - Dose Titration Period | 4 mg LY3502970 - Dose Titration Period | 8 mg LY3502970 - Dose Titration Period | 16 mg LY3502970 (Formulation 1) | 16 mg LY3502970 (Formulation 2) |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 13/38 | 3/37 | 6/34 | 6/33 | 4/34 |
| Decreased appetiteMetabolism and nutrition disorders | 13/38 | 2/37 | 2/34 | 0/33 | 3/34 |
| Catheter site erythemaGeneral disorders | 3/38 | 0/37 | 0/34 | 10/33 | 10/34 |
| Catheter site bruiseGeneral disorders | 1/38 | 0/37 | 0/34 | 9/33 | 3/34 |
| Abdominal distensionGastrointestinal disorders | 10/38 | 2/37 | 3/34 | 1/33 | 1/34 |
| NauseaGastrointestinal disorders | 9/38 | 3/37 | 6/34 | 2/33 | 5/34 |
| HeadacheNervous system disorders | 3/38 | 1/37 | 6/34 | 3/33 | 5/34 |
| Catheter site painGeneral disorders | 0/38 | 0/37 | 1/34 | 4/33 | 4/34 |
| Catheter site phlebitisGeneral disorders | 0/38 | 0/37 | 0/34 | 0/33 | 4/34 |
| DiarrhoeaGastrointestinal disorders | 2/38 | 0/37 | 2/34 | 3/33 | 2/34 |
All participants who received at least one dose of LY3502970.
| Age, Continuous(years) | 2 mg/4mg/8mg LY3502970 - Dose Titration Period |
|---|---|
| Mean | 40.4 ± 10.5 |
| Sex: Female, Male(Participants) | 2 mg/4mg/8mg LY3502970 - Dose Titration Period |
|---|---|
| Female | 4 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | 2 mg/4mg/8mg LY3502970 - Dose Titration Period |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 38 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | 2 mg/4mg/8mg LY3502970 - Dose Titration Period |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 38 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 2 mg/4mg/8mg LY3502970 - Dose Titration Period |
|---|---|
| Singapore | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Sep 2022, 3 months.
Results were first posted in May 2026, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron